(Reuters) - Ventana earlier said its board unanimously rejected the $75
per share hostile bid, which Roche first announced late last
month. Ventana said the bid -- which represented a 45 percent
premium at the time -- undervalues the company and its
prospects in the fast-growing cancer-testing market.
Asked whether Ventana preferred to remain a standalone
company, Gleeson said: "This is about value. It's not about
whether we want to stand alone or not, and we believe that the
value that is being offered today is nowhere near the value
that we believe this company can deliver."
Read more at Reuters.com Mergers News
per share hostile bid, which Roche first announced late last
month. Ventana said the bid -- which represented a 45 percent
premium at the time -- undervalues the company and its
prospects in the fast-growing cancer-testing market.
Asked whether Ventana preferred to remain a standalone
company, Gleeson said: "This is about value. It's not about
whether we want to stand alone or not, and we believe that the
value that is being offered today is nowhere near the value
that we believe this company can deliver."
Read more at Reuters.com Mergers News
No comments:
Post a Comment